2025 WCLC Public Disclosures

Phase I/II Study of iza-bren (BL-B01D1) as Monotherapy in Patients with pre-treated Locally Advanced or Metastatic EGFR Mutated NSCLC

Phase II Study of iza-bren (BL-B01D1) Combo with Osimertinib in EGFR Mutated Locally Advanced or Metastatic NSCLC Patients